2
2seventybio
Immuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment
About 2seventybio
2seventy bio is a biotechnology startup dedicated to revolutionizing cancer treatment. The company's name, inspired by the speed of translating human thought into action (270 miles per hour), reflects its commitment to rapidly advancing cancer therapies. 2seventy bio aims to give people more time to enjoy life by developing innovative treatments that outmaneuver cancer.
The company operates in the biotechnology and healthcare market, focusing on discovering and developing new cancer therapies. It combines deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer. This approach allows 2seventy bio to create treatments that can significantly disrupt the current cancer treatment landscape.
2seventy bio serves patients diagnosed with cancer, healthcare providers, and the broader medical community. Its business model revolves around research and development (R&D) of novel cancer therapies, which are then brought to market through clinical trials and regulatory approval processes. The company generates revenue by commercializing these therapies, either by selling them directly or through partnerships and collaborations with other pharmaceutical companies.
In summary, 2seventy bio is a forward-thinking biotech company focused on developing groundbreaking cancer treatments. By leveraging advanced scientific knowledge and innovative approaches, it aims to provide patients with more time to live their lives fully.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2021
News
Open roles
2seventybio in the Cambridge ecosystem
The 2seventybio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later11 investors entered at this stage
- CMCaaS Capital Management
- CICowen Healthcare Investments
Casdin Capital- 6C683 Capital
- RIRTW Investments
- ECEcoR1 Capital
- BSBain Capital Life Sciences
- ACArmistice Capital
Janus Henderson Investors
- BCBoxer Capital
- HMHeights Capital Management
Source: Dealroom Talent Intelligence.
Patents
41 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See 2seventybio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

